Track MAIA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$41.11M
Enterprise Value-$8.62B
Revenue (TTM)-
Net Income (TTM)-$22.40M
Free Cash Flow (TTM)-$18.84B
Financial Health
Cash$8.66B
Net Debt-$8.66B
Debt Ratio0
Debt to Equity0
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings-1.84
EV to EBITDA596.28
Price to Book0.02
Price to Free Cash Flow0
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-1190.90%
Return on Assets-177.66%
Return on Equity-1208.97%
Return on Total Capital-1190.90%
Return on Capital Employed-386.52%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue0.00%
Diluted EPS-0.72%
Total Debt-92.64%
Capital Expenditures0.00%
Free Cash Flow-99.12%
CAGR (3Y)
Revenue0.00%
Diluted EPS26.04%
Total Debt0.00%
Capital Expenditures0.00%
Free Cash Flow-99.96%
CAGR (1Y)
Revenue0.00%
Diluted EPS19.16%
Total Debt0.00%
Capital Expenditures0.00%
Free Cash Flow-100.00%
$1.32+$0.04|+3.03%
Last updated: Jul 21, 2:20 PM ET
52W High$3.19
52W Low$0.87
50D SMA$1.36
200D SMA$1.48
Volume315.69K
MAIA Biotechnology Inc.
444 West Lake Street, Chicago, IL, United States, 60606
IPO
2022
Employees
13
Industry
Biotechnology
Sector
Healthcare
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Insider Transactions
Quarterly buy vs. sell activity
No insider transactions data available for this period
Analyst Ratings
No coverage data
No analyst ratings data available